atomoxetine (Taihe Pharmaceutical)

TAH9922 is an oral liquid formulation of atomoxetine, a selective norepinephrine transporter (NET) inhibitor, developed by Taihe Pharmaceutical (Taho Pharma). It is specifically designed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients who may have difficulty swallowing capsules. By selectively inhibiting the presynaptic norepinephrine transporter, the drug increases the concentration of norepinephrine in the synaptic cleft, particularly in the prefrontal cortex, which is associated with improved attention and impulse control. TAH9922 is being developed via the 505(b)(2) regulatory pathway in the United States, and its US commercial rights have been licensed to a partner for NDA filing.

Other names

Atomoxetine Oral LiquidAtomoxetine Oral Solution